Dual GLP-1/GIP Receptor Agonists: Mechanism of Action, Metabolic Implications, and Drug Discovery Advantages

Dual GLP-1/GIP receptor agonists (molecules engineered to simultaneously activate GLP-1R and GIPR) represent a pharmacological leap beyond classical incretin-based therapies. By harnessing the complementary biology of two endogenous hormones, these agents achieve metabolic effects on glycemia, body weight, lipid handling, and cardiovascular risk that neither hormone can fully replicate alone. Understanding how this dual engagement works at the receptor and cellular level is increasingly relevant for both clinicians and drug discovery teams designing the next generation of incretin mimetics.

GIP and GLP-1 Receptor Signaling: How Simultaneous Activation Drives Synergistic Metabolic Effects

Both GLP-1R and GIPR belong to the class B GPCR family and signal primarily through the Gαs–cAMP pathway to promote glucose-dependent insulin secretion from pancreatic β-cells. Despite this shared mechanism, the two receptors exhibit distinct expression patterns and physiological roles that are genuinely complementary:

• GLP-1 enhances insulin secretion, suppresses glucagon under hyperglycemia, slows gastric emptying via vagal pathways, and engages hypothalamic and brainstem satiety circuits.
• GIP exerts glucagonotropic effects during hypoglycemia (preventing reactive hypoglycemia) and acts directly on white adipose tissue to facilitate lipid storage and improve insulin sensitivity. GIPR-expressing hypothalamic neurons contribute to appetite suppression in addition to GLP-1R signaling.

When both axes are activated concurrently, the cAMP response in pancreatic β-cells exceeds that of either agonist alone, indicating synergistic rather than merely additive intracellular signaling. Preclinical combination studies confirm that simultaneous GLP-1R and GIPR activation outperforms either receptor alone for weight reduction and glycemic control. This coordinated engagement across the pancreas, brain, gut, liver, and adipose tissue underlies the mechanistic rationale for dual GLP-1/GIP receptor agonists, and explains why they have been described as “super GLP-1RAs,” reflecting genuine potentiation of GLP-1 action by GIP receptor agonist co-activation.

Dual vs Single Receptor Agonism: Pharmacological Differences and Implications for Drug Design

Understanding the mechanism behind tirzepatide’s activity, and by extension, that of other dual GLP-1 / GIP receptor agonists, requires linking pharmacological profile to clinical outcomes. The innovation behind these drugs is the integration of GLP-1 agonistic activity into a GIP-based scaffold, achieving a synergistic, dual activation of both receptors. A key innovation was integrating GLP-1R agonism into a GIP peptide scaffold, achieving an agent capable of activating both receptors.

Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, is a 39-amino acid peptide with an approximately 120-hour half-life supporting once-weekly dosing. It is an imbalanced agonist with GIPR potency close to native GIP but weaker GLP-1R affinity, and shows biased GLP-1R signaling, favoring cAMP over β-arrestin recruitment. In SURPASS trials, it produced dose-dependent HbA1c reductions and weight loss consistently exceeding those of semaglutide.

Key differences in tirzepatide vs semaglutide mechanism of action relevant to drug design are:

• Receptor engagement: tirzepatide activates both GLP-1R and GIPR; semaglutide has no meaningful GIPR activity.
• Metabolic effects: the tirzepatide mode of action yields greater improvements in β-cell function, insulin sensitivity, and glucagon suppression, alongside superior tirzepatide weight loss mechanism of action outcomes.
• GIPR contributions: GIPR co-activation supports adipose tissue remodeling and may attenuate GLP-1-related gastrointestinal intolerance.

Clinical comparisons between tirzepatide and the more balanced RG7697, whose efficacy approximated liraglutide, confirm that receptor activity ratio and signaling bias are as consequential as dual engagement itself.

Studying Dual GLP-1/GIP Receptor Activation in Preclinical Models: Fluorescent Assay Strategies and Binding Tools

Translating the pharmacology of dual GLP-1/GIP agonists into actionable preclinical data requires tools capable of detecting receptor engagement with cellular and spatial resolution, challenging because GLP-1R and GIPR are low-abundance membrane proteins, and no reliable commercial antibody exists for GIPR detection in primary tissues.

Figure 1. daLUXendin660+ labels islets with strength of labelling β cells > α cells = δ cells. (INS = insulin, GCG = glucagon, SST = somatostatin). Adapted from: de Bray A, et al. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain. Nat Metab. 2025 Aug;7(8):1536-1549.

Fluorescent ligand-based strategies have emerged as powerful solutions. De Bray et al. (2025, Nature Metabolism) reported daLUXendin and daLUXendin+, non-lipidated and lipidated dual GLP-1/GIP receptor agonist fluorescent probes with nanomolar affinity at both hGLP1R and hGIPR. Key findings include:

• Pancreatic islet targeting: daLUXendins label rodent and human islet cells with a signal hierarchy of β cells > α cells = δ cells, providing the first direct cellular-scale mapping of dual-agonist-like binding in primary islets.
• Brain access via circumventricular organs: systemic administration labels GLP-1R⁺ and GIPR⁺ neurons in circumventricular organs without deeper brain penetration, demonstrating that enhanced brain access does not account for dual agonist superiority over single agonists.
• Nanoscale receptor organization: daLUXendin660 engages more ordered GLP-1R/GIPR nanodomains than single agonist probes, suggesting dual agonism influences receptor clustering beyond simple co-activation.

These GLP-1/GIP receptor agonist probes are designed for functional in vivo studies. After systemic administration, they engage both GLP1R and GIPR simultaneously in native tissue, enabling the study of receptor engagement, metabolic responses, and therapeutic effects at the cellular and organ level, going beyond localization to provide functional readouts directly in living models. 

Beyond Tirzepatide: Next-Generation Dual and Triple Incretin Agonists in the Drug Discovery Pipeline

Tirzepatide has established proof-of-concept for the GIP/GLP-1 receptor agonist mechanism of action, but the pipeline extends further. The key question driving next-generation design is whether adding the glucagon receptor (GcgR) to dual GLP-1/GIP agonists can unlock additional efficacy.

Preclinical work with GLP-1R/GIPR/GcgR triple agonists showed that a balanced triple agonist produced greater body-weight loss than semaglutide, tirzepatide, and dual co-agonists in diet-induced obese mice, reducing weight to near-lean levels at the highest doses. This superiority came not from greater food intake suppression but from measurably increased energy expenditure. GIPR agonism proved essential, buffering the hyperglycemic liability of GcgR activation.

Clinically, retatrutide is the most advanced triple agonist, with network meta-analyses identifying it as achieving the greatest weight reduction in the incretin class to date. The divergent profiles across dual GLP-1/GIP agonists and triple agonists targeting GIP receptor agonist biology underscore that receptor activity ratios, biased signaling, and tissue-level receptor access remain central questions for the field.

Characterizing dual GLP-1/GIP receptor agonists demands tools that resolve receptor engagement with specificity and spatial resolution that conventional approaches cannot provide. Our daLUXendin+ probes (pharmacologically validated dual GLP-1R/GIPR fluorescent agonists compatible with confocal microscopy,single-molecule imaging, and in vivo functional studies) are designed precisely for this. 

Contact us to learn how our platform can accelerate your program!

References

de Bray A, Roberts AG, Armour S, Tong J, Huhn C, Gatin-Fraudet B, Roßmann K, Shilleh AH, Jiang W, Figueredo Burgos NS, Trott JPP, Viloria K, Nasteska D, Pearce A, Miyazaki S, Tomlinson JW, Owen DM, Nieves DJ, Ast J, Cyranka M, Epanchintsev A, Ämmälä C, Reimann F, Soykan T, Ladds G, Adriaenssens AE, Trapp S, Jones B, Broichhagen J, Hodson DJ. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain. Nat Metab. 2025 Aug;7(8):1536-1549. doi: 10.1038/s42255-025-01342-6

Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjøllund KR, He Y, Kruse Hansen AM, Olsen AK, Perez-Tilve D, DiMarchi RD, Finan B. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022 Sep;63:101533. doi: 10.1016/j.molmet.2022.101533. 

Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. doi: 10.3389/fendo.2024.1431292. 

Mayendraraj A, Rosenkilde MM, Gasbjerg LS. GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation. Peptides. 2022 May;151:170749. doi: 10.1016/j.peptides.2022.170749. 

Scheen AJ. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Ann Endocrinol (Paris). 2023 Apr;84(2):316-321. doi: 10.1016/j.ando.2022.12.423. 

Yan K, Yu H, Blaise B. Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis. Acta Diabetol. 2025 Sep;62(9):1359-1370. doi: 10.1007/s00592-025-02534-y.